Literature DB >> 17512011

Treatment of spinocerebellar ataxia with buspirone.

Mitra Assadi1, Joseph V Campellone, Christopher G Janson, J Jon Veloski, Robert J Schwartzman, Paola Leone.   

Abstract

Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17512011     DOI： 10.1016/j.jns.2007.04.019

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  Current concepts in the treatment of hereditary ataxias.

Authors:  Pedro Braga Neto; José Luiz Pedroso; Sheng-Han Kuo; C França Marcondes Junior; Hélio Afonso Ghizoni Teive; Orlando Graziani Povoas Barsottini
Journal:  Arq Neuropsiquiatr       Date:  2016-03       Impact factor: 1.420

Review 2.  Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials.

Authors:  Jonas Alex Morales Saute; Karina Carvalho Donis; Carmen Serrano-Munuera; David Genis; Luís Torres Ramirez; Pilar Mazzetti; Luis Velázquez Pérez; Pilar Latorre; Jorge Sequeiros; Antoni Matilla-Dueñas; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

3.  Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Theresa A Zesiewicz; George Wilmot; Sheng-Han Kuo; Susan Perlman; Patricia E Greenstein; Sarah H Ying; Tetsuo Ashizawa; S H Subramony; Jeremy D Schmahmann; K P Figueroa; Hidehiro Mizusawa; Ludger Schöls; Jessica D Shaw; Richard M Dubinsky; Melissa J Armstrong; Gary S Gronseth; Kelly L Sullivan
Journal:  Neurology       Date:  2018-02-09       Impact factor: 9.910

4.  Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.

Authors:  Nupur Nag; Volga Tarlac; Elsdon Storey
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

5.  Therapeutic interventions in the primary hereditary ataxias.

Authors:  Gonzalo J Revuelta; George R Wilmot
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study.

Authors:  Asako Takei; Shinsuke Hamada; Sanae Homma; Keiko Hamada; Kunio Tashiro; Takeshi Hamada
Journal:  Cerebellum       Date:  2010-12       Impact factor: 3.847

Review 7.  Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials.

Authors:  Ji-Hyun Choi; Chaewon Shin; Han-Joon Kim; Beomseok Jeon
Journal:  J Neurol       Date:  2020-11-20       Impact factor: 4.849

Review 8.  Current and emerging treatment modalities for spinocerebellar ataxias.

Authors:  Shaila D Ghanekar; Sheng-Han Kuo; Joseph S Staffetti; Theresa A Zesiewicz
Journal:  Expert Rev Neurother       Date:  2022-02-10       Impact factor: 4.287

9.  Consensus paper: management of degenerative cerebellar disorders.

Authors:  W Ilg; A J Bastian; S Boesch; R G Burciu; P Celnik; J Claaßen; K Feil; R Kalla; I Miyai; W Nachbauer; L Schöls; M Strupp; M Synofzik; J Teufel; D Timmann
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

Review 10.  Treatment Options in Degenerative Cerebellar Ataxia: A Systematic Review.

Authors:  Harini Sarva; Vicki Lynn Shanker
Journal:  Mov Disord Clin Pract       Date:  2014-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.